Linked Life Data

6134331

Source:http://linkedlifedata.com/resource/pubmed/id/6134331

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1983-7-15
pubmed:abstractText
Three randomised therapeutic protocols were studied: thyrocalcitonin, beta-blockers and the combination of Grisefuline + Penthonium, in a group of 95 cases of algodystrophy (64 women, 31 men). These cases were divided into four groups: upper limb, lower limb, "recent" or "long-standing". The results were assessed after one month of treatment. A positive result was defined as being an improvement of more than 50 p. cent of the clinical subjective and objective criteria; less than that, the activity is uncertain or nil. Comparison of the results did not reveal any statistically significant difference between the three proposed treatments, whether we consider the whole group of patients or each sub-group separately (overall positive results: Calsyn 100 = 53 p. cent, Visken = 42,5 p. cent, Grisefuline + Penthonium = 53 p. cent). The important role played by rehabilitation must be stressed. It should be discontinued during the acute phase and instituted in the later phase. Cure is obtained after an average of 4-5 months of treatment. 10 patients were left with major trophic sequelae after 2 years of the disease; all involve the hand.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0035-2659
pubmed:author
pubmed:issnType
Print
pubmed:volume
50
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
95-7
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1983
pubmed:articleTitle
[Treatment of algodystrophy. A randomized study of 95 cases with 3 treatments: Calsyn 100, Visken, Grisefuline and Penthonium].
pubmed:publicationType
Journal Article, Clinical Trial, English Abstract, Randomized Controlled Trial